Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 21,083

Document Document Title
WO/2016/052656A1
An autophagy inducing agent that comprises at least one member selected from a compound represented by structural formula (A), a compound represented by structural formula (B), and a compound represented by structural formula (C).  
WO/2016/049884A1
Provided are a conotoxin polypeptide κ-CPTx-bt105, a method for preparation thereof, and an application thereof. The conotoxin polypeptide consists of 16 amino acids, has a molecular weight of 1626.62 daltons, and has the full sequence ...  
WO/2016/049864A1
Disclosed are a conotoxin polypeptide κ-CPTx-bt101, a method for preparation thereof, and an application thereof. The conotoxin polypeptide of the present invention consists of 18 amino acids, has a molecular weight of 1872.72 daltons, ...  
WO/2016/049746A1
Described are methods of producing an autologous composition useful for treatment of damaged and/or injured connective tissues, chronic tendinosis, chronic muscle tears and/or chronic degenerative joint conditions and skin inflammatory d...  
WO/2016/049881A1
Provided are a conotoxin polypeptide κ-CPTx-bt104, a method for preparation thereof, and an application thereof. The conotoxin polypeptide consists of 11 amino acids, has a molecular weight of 1313.47 daltons, and has the full sequence ...  
WO/2016/049873A1
Provided are a conotoxin polypeptide κ-CPTx-bt103, a method for preparation thereof, and an application thereof. The conotoxin polypeptide consists of 29 amino acids, has a molecular weight of 3141.43 daltons, and has the full sequence ...  
WO/2016/049869A1
Disclosed are a conotoxin polypeptide κ-CPTx-bt102, a method for preparation thereof, and an application thereof. The conotoxin polypeptide of the present invention consists of 15 amino acids, has a molecular weight of 1660.61 daltons, ...  
WO/2016/046759A3
The invention provides compositions and methods useful for the treatment of Friedreich's ataxia. In some embodiments, the invention provides compositions and methods useful for inhibiting the ubiquitination of frataxin.  
WO/2016/044167A1
Methods of increasing muscle strength and mobility in a subject experiencing significant physical inactivity include administering gamma linolenic acid to the subject as part of a nutritional composition containing fat and at least one o...  
WO/2016/044635A1
Methods of rehabilitation of neurological disorders, including neurological deficits associated with neurotraumas, such as stroke and traumatic brain injury, and with muscle disorders, that includes administering to a subject a MAO-B inh...  
WO/2016/044272A1
Methods of preserving muscle strength in a subject during a period of muscle disuse are provided. Methods of preserving muscle strength in a subject during a period of muscle disuse and a subsequent period of muscle recovery are also pro...  
WO/2016/041192A1
Disclosed is a use of ligustilide, comprising a use of ligustilide to improve a therapeutic benefit of a stem cell, and a use of ligustilide and a stem cell treated therewith in a stem cell treatment. Treating the stem cell via the ligus...  
WO/2016/044796A1
The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol.  
WO/2016/040801A1
The invention provides therapeutic methods comprising the administration of thymol or carvacrol, or a pharmaceutically acceptable salt or prodrug thereof. The methods are useful for modulating muscle atrophy, performance, recovery, gener...  
WO/2016/039359A1
The present invention relates to: a terpenoid derivative which is capable of activating a Keap1/Nrf2/ARE signaling pathway and has an excellent anti-inflammatory activity and an excellent cell-protecting activity; and a sustained-release...  
WO/2016/040234A1
The present invention provides a method of treating symptoms associated with Androgen Deprivation Therapy comprising administering to a patient in need of such treatment an effective amount of a compound of Formula I: [Formula should be ...  
WO/2016/035182A1
[Problem] The purpose of the present invention is to provide a composition that is a ginsenoside composition derived from medicinal ginseng and that is particularly useful as a composition for oral use. [Solution] Provided is a compositi...  
WO/2016/035934A1
The present invention relates to a human cell model of GM1 gangliosidosis, induced pluripotent stem cells (iPSCs) thereof, a method for preparing model cells based on neural progenitor cells derived from the iPSCs, and a use for the GM1 ...  
WO/2016/030323A1
The present invention relates to the use of elafin for the treatment and/or prevention of diseases or disorders associated with an increase in troponin levels, which are non elastase dependent. The present invention in a preferred embodi...  
WO/2016/031987A1
A compound represented by any of formulas (Ia)-(Ic) or formula (II), or a pharmaceutically acceptable salt thereof. (In the formulas, R1, R2, R3, R4a, R4c, R5, R15, ring A, X1, and X2 are as defined in the specification.)  
WO/2016/031264A1
The present invention addresses the problem of providing a new therapeutic strategy for an ailment wherein skeletal muscle loss is the main cause or partial cause of the ailment. Provided is a skeletal muscle bulking agent containing mec...  
WO/2016/028971A1
The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inven...  
WO/2016/028894A1
Uridine triacetate or other uridine prodrugs are used to treat genetic glycosylation disorders by administering them in an amount sufficient to raise plasma uridine in the to a level greater than 30 micromolar. They can be administered a...  
WO/2016/027225A1
A pharmaceutical composition or dietary supplement having a muscle-relaxant and anti¬ inflammatory activity is described, which is effective in the treatment of muscle, bone, articular and tendon pathologies, comprising, as active ingre...  
WO/2016/027225A8
A pharmaceutical composition or dietary supplement having a muscle-relaxant and anti¬ inflammatory activity is described, which is effective in the treatment of muscle, bone, articular and tendon pathologies, comprising, as active ingre...  
WO/2016/025339A3
The present invention relates to the delivery of oligomers for treating patients with a 5' mutation in their DMD gene other than a DMD exon 2 duplication. The invention provides methods and materials for activating an internal ribosome e...  
WO/2016/016507A1
The invention relates to a method for diagnosing fibromyalgia using microRNAs. The invention provides a method for molecular diagnosis of fibromyalgia patients, based on analysing the possible alteration of the levels of certain microRNA...  
WO/2016/017767A1
Provided are: a novel Sirtuin-1 activator; and a preparation for preventing the occurrence of oxidative stress-induced cellular senescence, which contains the Sirtuin-1 activator. The present invention provides: a Sirtuin-1 activator whi...  
WO/2016/012398A1
The present invention relates to a novel pharmaceutical composition comprising zaitoprofen or a pharmaceutically acceptable salt thereof in combination with muscle relaxants with anti-inflammatory, analgesic and myorelaxant activity.  
WO/2016/008034A1
This invention relates to a method of increasing energy available to skeletal muscle cells comprising administering to the cells an effective amount of Tenurin C-terminal Associated Peptide (TCAP). The invention provides the use of TCAP ...  
WO/2016/008966A1
The present invention relates to methods for treating neuromuscular junction-related diseases. In particular, the present invention relates to a method of treating a neuromuscular junction-related disease in a subject in need thereof com...  
WO/2016/011420A1
This invention provides methods, compounds and compositions for the treatment of musculoskeletal disease, muscle dysfunction, muscle-wasting disease or disorder, including hereditary myopathy, neuromuscular disease, muscular dystrophy, m...  
WO/2016/011348A1
Potent modulators of RNA function can be assembled in cellulo by using the cell as a reaction vessel and a disease-causing RNA as a catalyst. When designing small molecule effectors of function, a balance between permeability and potency...  
WO/2016/011019A1
The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, an...  
WO/2016/005527A1
The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, where in the administering step provides an average patient's maximum p...  
WO/2016/004882A1
Provided herein are aromatic heterocyclic derivatives or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof used for treating Alzheimer's disease. Also provided herein...  
WO/2016/006996A1
The present invention relates to a therapeutic tape comprising stretchable base cloth formed from the material of a kinesiology tape; an adhesive layer provided on one side of the base cloth; and a composition of non-steroidal anti- infl...  
WO/2016/001762A1
The present disclosure relates to the use of the non-toxic proteolytic C fragment of tetanus toxin and plasmids encoding such protein fragment to increase muscle mass and/or muscle strength in a subject in need thereof. As such, methods ...  
WO/2016/002948A1
The purpose of the present invention is to provide a lysophosphatidylserine derivative or salt thereof. The present invention provides a lysophosphatidylserine derivative or salt thereof, and a pharmaceutical composition or lysophosphati...  
WO/2015/199169A1
Provided is a composition that includes: a tea extract or a catechin; and a citrus fruit extract or a flavanone, or a glucoside thereof.  
WO/2015/197503A1
The present invention provides compounds of formula (I) wherein A, Xl, X2, R1, R2, R3, R4and R5are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture...  
WO/2015/194520A1
Provided is a drug that provides highly efficient exon skipping. The present invention provides an antisense oligomer having at least two unit oligomers linked that target arrays that are do not continue on from or overlap with each othe...  
WO/2015/188943A1
This invention relates to novel uses of recombinant clostridial neurotoxins exhibiting decreased duration of effect, in particular uses for the treatment of patients having experienced muscle-related disorders and/or injuries.  
WO/2015/188944A1
This invention relates to novel uses of recombinant clostridial neurotoxins exhibiting decreased duration of effect, in particular uses for the treatment of patients having experienced tendon-related disorders and/or injuries.  
WO/2015/191827A1
A method for reducing muscle damage and/or oxidative stress in active mammals as disclosed. In one embodiment, the mammals are administered a carnitine supplement. The L-carnitine supplement may be administered without any other pharmace...  
WO/2015/190643A1
The present invention relates to a composition for promoting the differentiation of myoblasts, the composition containing butylpyridinium, a derivative thereof, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition ...  
WO/2015/189534A1
The invention relates to the use of compounds which inhibit VAP-1 /SSAO activity for the treatment of muscular dystrophy. The invention also relates to combined preparations comprising compounds which inhibit VAP-1 /SSAO activity, and th...  
WO/2015/188942A1
This invention relates to novel uses of recombinant clostridial neurotoxins exhibiting decreased duration of effect, in particular uses for the treatment of patients suffering from a limited range of muscle extension, in particular from ...  
WO/2015/188945A1
This invention relates to novel uses of recombinant clostridial neurotoxins exhibiting decreased duration of effect, in particular uses for the treatment of different forms of back pain, in particular recurrent low back pain.  
WO/2015/187977A1
The present invention relates to follistatin-Fc fusion proteins that have effects in the tissue of administration (such as an injected muscle), rather than systemic effects. The Fc domain results in dimerization of the follistatin-Fc fus...  

Matches 101 - 150 out of 21,083